BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23069940)

  • 1. BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.
    Ellmann L; Joshi MB; Resink TJ; Bosserhoff AK; Kuphal S
    Lab Invest; 2012 Dec; 92(12):1788-800. PubMed ID: 23069940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene.
    Kobi D; Steunou AL; Dembélé D; Legras S; Larue L; Nieto L; Davidson I
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):404-18. PubMed ID: 20337985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRN2 is a non-canonical melanoma tumor-suppressor.
    Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
    Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
    Herbert K; Binet R; Lambert JP; Louphrasitthiphol P; Kalkavan H; Sesma-Sanz L; Robles-Espinoza CD; Sarkar S; Suer E; Andrews S; Chauhan J; Roberts ND; Middleton MR; Gingras AC; Masson JY; Larue L; Falletta P; Goding CR
    Genes Dev; 2019 Mar; 33(5-6):310-332. PubMed ID: 30804224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
    Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
    Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
    EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
    Boyle GM; Woods SL; Bonazzi VF; Stark MS; Hacker E; Aoude LG; Dutton-Regester K; Cook AL; Sturm RA; Hayward NK
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):525-37. PubMed ID: 21435193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLI2 cooperates with ZEB1 for transcriptional repression of CDH1 expression in human melanoma cells.
    Perrot CY; Gilbert C; Marsaud V; Postigo A; Javelaud D; Mauviel A
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):861-73. PubMed ID: 23890107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB.
    Katoh M; Katoh M
    Int J Oncol; 2009 Jun; 34(6):1737-42. PubMed ID: 19424592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H-cadherin expression reduces invasion of malignant melanoma.
    Kuphal S; Martyn AC; Pedley J; Crowther LM; Bonazzi VF; Parsons PG; Bosserhoff AK; Hayward NK; Boyle GM
    Pigment Cell Melanoma Res; 2009 Jun; 22(3):296-306. PubMed ID: 19368692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer.
    Sakaeda M; Sato H; Ishii J; Miyata C; Kamma H; Shishido-Hara Y; Shimoyamada H; Fujiwara M; Endo T; Tanaka R; Kondo H; Goya T; Aoki I; Yazawa T
    Lab Invest; 2013 Apr; 93(4):408-21. PubMed ID: 23358112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway.
    Thurber AE; Douglas G; Sturm EC; Zabierowski SE; Smit DJ; Ramakrishnan SN; Hacker E; Leonard JH; Herlyn M; Sturm RA
    Oncogene; 2011 Jul; 30(27):3036-48. PubMed ID: 21358674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma.
    Bosserhoff AK; Ellmann L; Quast AS; Eberle J; Boyle GM; Kuphal S
    Mol Carcinog; 2014 Aug; 53(8):635-47. PubMed ID: 23625515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.
    Flammiger A; Besch R; Cook AL; Maier T; Sturm RA; Berking C
    J Invest Dermatol; 2009 Apr; 129(4):945-53. PubMed ID: 18923447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
    Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
    Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas.
    Qian ZR; Sano T; Yoshimoto K; Asa SL; Yamada S; Mizusawa N; Kudo E
    Mod Pathol; 2007 Dec; 20(12):1269-77. PubMed ID: 17873891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression.
    Maeda G; Chiba T; Okazaki M; Satoh T; Taya Y; Aoba T; Kato K; Kawashiri S; Imai K
    Int J Oncol; 2005 Dec; 27(6):1535-41. PubMed ID: 16273209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
    Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
    Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
    Simmons JL; Pierce CJ; Al-Ejeh F; Boyle GM
    Sci Rep; 2017 Sep; 7(1):10909. PubMed ID: 28883623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.